OvaScience Company Profile (NASDAQ:OVAS)

About OvaScience (NASDAQ:OVAS)

OvaScience logoOvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company's portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient's own ovarian tissue. The Company's AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman's ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman's own EggPC cells without the need for hormone hyperstimulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OVAS
  • CUSIP: N/A
  • Web: www.ovascience.com
Capitalization:
  • Market Cap: $50.32 million
  • Outstanding Shares: 35,686,000
Average Prices:
  • 50 Day Moving Avg: $1.40
  • 200 Day Moving Avg: $1.45
  • 52 Week Range: $1.25 - $6.26
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.11
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $465,000.00
  • Price / Sales: 108.98
  • Book Value: $2.27 per share
  • Price / Book: 0.63
Profitability:
  • EBITDA: ($62,550,000.00)
  • Net Margins: -16,132.47%
  • Return on Equity: -69.13%
  • Return on Assets: -61.52%
Debt:
  • Current Ratio: 7.54%
  • Quick Ratio: 7.54%
Misc:
  • Average Volume: 207,777 shs.
  • Beta: 3.51
  • Short Ratio: 12.23
 

Frequently Asked Questions for OvaScience (NASDAQ:OVAS)

What is OvaScience's stock symbol?

OvaScience trades on the NASDAQ under the ticker symbol "OVAS."

How were OvaScience's earnings last quarter?

OvaScience Inc. (NASDAQ:OVAS) announced its earnings results on Thursday, August, 3rd. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.02. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. OvaScience had a negative return on equity of 69.13% and a negative net margin of 16,132.47%. The company's revenue was down 55.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.62) EPS. View OvaScience's Earnings History.

When will OvaScience make its next earnings announcement?

OvaScience is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for OvaScience.

Where is OvaScience's stock going? Where will OvaScience's stock price be in 2017?

3 brokerages have issued 12-month target prices for OvaScience's shares. Their forecasts range from $1.00 to $15.00. On average, they expect OvaScience's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for OvaScience.

Who are some of OvaScience's key competitors?

Who are OvaScience's key executives?

OvaScience's management team includes the folowing people:

  • Chris A. Kroeger M.D., Chief Executive Officer
  • Jonathan Gillis, principal Financial Officer, principal Accounting Officer, Vice President
  • Karen Long, Executive Vice President - Clinical and Regulatory Affairs and Quality Assurance
  • James Luterman Ph.D., Executive Vice President - Research and Development
  • Theresa McNeely, Executive Vice President, Chief Communications Officer
  • Ravi Mehrotra Ph.D., Chief Corporate Development Officer
  • Richard H. Aldrich, Lead Independent Director
  • John P. Howe III M.D., Director
  • John E. Sexton Ph.D., Director
  • Jeffrey D. Capello, Independent Director

How do I buy OvaScience stock?

Shares of OvaScience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OvaScience's stock price today?

One share of OvaScience stock can currently be purchased for approximately $1.42.


MarketBeat Community Rating for OvaScience (NASDAQ OVAS)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OvaScience (NASDAQ:OVAS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.00 (463.38% upside)
Consensus Price Target History for OvaScience (NASDAQ:OVAS)
Price Target History for OvaScience (NASDAQ:OVAS)
Analysts' Ratings History for OvaScience (NASDAQ:OVAS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
5/12/2017HC WainwrightReiterated RatingBuy$15.00LowView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingUnderperform -> Underperform$1.00LowView Rating Details
8/10/2016JMP SecuritiesReiterated RatingNeutralN/AView Rating Details
8/5/2016J P Morgan Chase & CoLower Price TargetNeutral$9.00 -> $8.00N/AView Rating Details
5/8/2016Leerink SwannReiterated RatingHold$6.00 -> $7.00N/AView Rating Details
3/21/2016S&P Equity ResearchLower Price Target$10.82 -> $8.83N/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for OvaScience (NASDAQ:OVAS)
Earnings by Quarter for OvaScience (NASDAQ:OVAS)
Earnings History by Quarter for OvaScience (NASDAQ OVAS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.39)N/AView Earnings Details
8/3/2017Q2 2017($0.47)($0.45)$0.09 million$0.08 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.46)($0.38)$0.12 million$0.06 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.58)($0.64)$0.11 million$0.12 millionViewListenView Earnings Details
11/3/2016Q316($0.62)($0.54)$0.25 million$0.02 millionViewListenView Earnings Details
8/4/2016Q216($0.78)($0.62)$0.21 million$0.19 millionViewListenView Earnings Details
5/5/2016Q116($0.72)($0.80)$0.14 million$0.15 millionViewListenView Earnings Details
2/25/2016Q315($0.71)($0.76)$0.20 million$0.16 millionViewListenView Earnings Details
11/5/2015Q3($0.68)($0.66)$0.17 million$0.08 millionViewN/AView Earnings Details
8/10/2015Q215($0.64)($0.64)$0.57 million$0.03 millionViewN/AView Earnings Details
5/11/2015($0.65)($0.65)$0.40 million$0.02 millionViewN/AView Earnings Details
3/16/2015Q414($0.59)($0.79)ViewN/AView Earnings Details
11/10/2014Q314($0.44)($0.54)ViewN/AView Earnings Details
8/7/2014Q214($0.45)($0.42)ViewN/AView Earnings Details
5/8/2014($0.46)($0.41)ViewN/AView Earnings Details
2/27/2014Q413($0.39)($0.64)ViewN/AView Earnings Details
11/13/2013Q313($0.35)($0.40)ViewN/AView Earnings Details
8/13/2013Q213($0.28)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OvaScience (NASDAQ:OVAS)
2017 EPS Consensus Estimate: ($1.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.35)($0.35)($0.35)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.41)($0.41)($0.41)
Q4 20171($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OvaScience (NASDAQ:OVAS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OvaScience (NASDAQ:OVAS)
Insider Ownership Percentage: 9.50%
Institutional Ownership Percentage: 56.28%
Insider Trades by Quarter for OvaScience (NASDAQ:OVAS)
Institutional Ownership by Quarter for OvaScience (NASDAQ:OVAS)
Insider Trades by Quarter for OvaScience (NASDAQ:OVAS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2016Michelle DippCEOBuy425,000$7.00$2,975,000.00View SEC Filing  
5/18/2016Michelle DippCEOBuy20,000$7.86$157,200.00View SEC Filing  
5/17/2016Michelle DippCEOBuy40,000$7.63$305,200.00View SEC Filing  
5/13/2016Richard AldrichDirectorBuy36,095$6.94$250,499.30View SEC Filing  
5/11/2016Richard AldrichDirectorBuy20,000$7.64$152,800.00View SEC Filing  
5/10/2016Michelle DippCEOBuy19,900$7.72$153,628.00View SEC Filing  
5/10/2016Paul W.D. ChapmanCOOBuy3,100$7.37$22,847.00View SEC Filing  
3/24/2016Michelle DippCEOBuy59,800$9.49$567,502.00View SEC Filing  
3/22/2016Michelle DippCEOBuy59,800$10.44$624,312.00View SEC Filing  
3/18/2016Michelle DippCEOBuy59,700$8.26$493,122.00View SEC Filing  
3/16/2016Michelle DippCEOBuy59,029$7.90$466,329.10View SEC Filing  
3/14/2016Michelle DippCEOBuy162,732$7.60$1,236,763.20View SEC Filing  
10/5/2015Jeffrey E YoungCFOBuy3,450$10.70$36,915.00View SEC Filing  
10/5/2015Marc D KozinDirectorBuy4,800$10.79$51,792.00View SEC Filing  
9/9/2015Mary FisherDirectorBuy6,100$16.49$100,589.00View SEC Filing  
9/8/2015Marc D KozinDirectorBuy3,000$17.60$52,800.00View SEC Filing  
4/8/2015Marc D KozinDirectorBuy3,000$28.45$85,350.00View SEC Filing  
4/2/2015Michelle DippCEOBuy1,000$32.49$32,490.00View SEC Filing  
1/13/2015Thomas MalleyDirectorBuy35,000$50.00$1,750,000.00View SEC Filing  
7/7/2014Richard AldrichDirectorBuy2,000$9.49$18,980.00View SEC Filing  
6/30/2014Richard AldrichDirectorBuy2,000$9.16$18,320.00View SEC Filing  
6/23/2014Richard AldrichDirectorBuy2,000$8.81$17,620.00View SEC Filing  
6/16/2014Richard AldrichDirectorBuy2,000$8.52$17,040.00View SEC Filing  
6/9/2014Richard AldrichDirectorBuy2,000$7.59$15,180.00View SEC Filing  
6/3/2014Harald F StockDirectorBuy1,063$7.01$7,451.63View SEC Filing  
6/2/2014Richard AldrichDirectorBuy2,000$7.29$14,580.00View SEC Filing  
5/27/2014Richard AldrichDirectorBuy2,000$7.50$15,000.00View SEC Filing  
5/20/2014Harald F StockDirectorBuy1,050$7.13$7,486.50View SEC Filing  
5/19/2014Richard AldrichDirectorBuy2,000$7.33$14,660.00View SEC Filing  
3/7/2014Fund L.P. LongwoodMajor ShareholderBuy100,000$10.00$1,000,000.00View SEC Filing  
9/12/2013Arthur TzianabosInsiderBuy1,000$10.32$10,320.00View SEC Filing  
9/12/2013Harald F StockDirectorBuy4,500$10.64$47,880.00View SEC Filing  
9/11/2013Christopher A BleckInsiderBuy2,000$11.15$22,300.00View SEC Filing  
9/11/2013Richard AldrichDirectorBuy4,850$10.54$51,119.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for OvaScience (NASDAQ:OVAS)
Latest Headlines for OvaScience (NASDAQ:OVAS)
Source:
DateHeadline
marketwatch.com logoIn-Vitro Fertilization Market to Reach US $725.9 Million by the end of 2022, Globally: Transparency Market Research
www.marketwatch.com - October 9 at 11:13 PM
americanbankingnews.com logoZacks Investment Research Upgrades OvaScience Inc. (OVAS) to Buy
www.americanbankingnews.com - October 8 at 9:56 PM
americanbankingnews.com logoOvaScience Inc. (OVAS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 8 at 12:34 PM
americanbankingnews.com logoZacks: Analysts Expect OvaScience Inc. (OVAS) Will Announce Quarterly Sales of $90,000.00
www.americanbankingnews.com - October 8 at 4:04 AM
finance.yahoo.com logoETFs with exposure to OvaScience, Inc. : October 5, 2017
finance.yahoo.com - October 5 at 2:34 PM
finance.yahoo.com logoETFs with exposure to OvaScience, Inc. : September 25, 2017
finance.yahoo.com - October 3 at 2:16 AM
americanbankingnews.com logo$100,000.00 in Sales Expected for OvaScience Inc. (OVAS) This Quarter
www.americanbankingnews.com - September 19 at 1:34 AM
streetinsider.com logoForm 3 OvaScience, Inc. For: Sep 01 Filed by: Kroeger Christopher A. - StreetInsider.com
www.streetinsider.com - September 12 at 8:20 AM
finance.yahoo.com logoETFs with exposure to OvaScience, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 8:20 AM
americanbankingnews.com logoReviewing OvaScience (OVAS) and Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - September 4 at 12:34 PM
finance.yahoo.com logoETFs with exposure to OvaScience, Inc. : August 31, 2017
finance.yahoo.com - September 1 at 6:58 AM
americanbankingnews.com logo Brokerages Expect OvaScience Inc. (OVAS) Will Announce Quarterly Sales of $100,000.00
www.americanbankingnews.com - September 1 at 5:22 AM
finance.yahoo.com logoOvaScience, Inc. :OVAS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 10:43 AM
finance.yahoo.com logoEdited Transcript of OVAS earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 13 at 7:54 PM
americanbankingnews.com logoOvaScience Inc. (NASDAQ:OVAS) Sees Significant Decline in Short Interest
www.americanbankingnews.com - August 12 at 3:08 AM
americanbankingnews.com logo-$0.43 EPS Expected for OvaScience Inc. (NASDAQ:OVAS) This Quarter
www.americanbankingnews.com - August 12 at 2:14 AM
americanbankingnews.com logoAnalyzing Ampliphi Biosciences Corp (APHB) & OvaScience (NASDAQ:OVAS)
www.americanbankingnews.com - August 6 at 7:54 AM
americanbankingnews.com logoOvaScience Inc. (OVAS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 4 at 7:44 AM
reuters.com logoBRIEF-Ovascience Q2 loss per share $0.51
www.reuters.com - August 4 at 6:45 AM
finance.yahoo.com logoOvaScience Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 6:45 AM
finance.yahoo.com logoOvaScience reports 2Q loss
finance.yahoo.com - August 4 at 6:45 AM
americanbankingnews.com logoOvaScience Inc. (NASDAQ:OVAS) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - August 3 at 7:02 PM
businesswire.com logoOvaScience to Host Second Quarter 2017 Financial Results Conference Call - Business Wire (press release)
www.businesswire.com - July 29 at 6:08 AM
finance.yahoo.com logoOvaScience to Host Second Quarter 2017 Financial Results Conference Call
finance.yahoo.com - July 28 at 6:35 AM
americanbankingnews.com logoShort Interest in OvaScience Inc. (NASDAQ:OVAS) Grows By 34.3%
www.americanbankingnews.com - July 27 at 7:06 AM
americanbankingnews.com logoOvaScience Inc. (OVAS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 10 at 9:55 AM
streetinsider.com logoForm 4 OvaScience, Inc. For: Jun 21 Filed by: ALDRICH RICHARD - StreetInsider.com
www.streetinsider.com - June 24 at 7:37 PM
streetinsider.com logoForm 3 OvaScience, Inc. For: Jun 21 Filed by: GILLIS JONATHAN - StreetInsider.com
www.streetinsider.com - June 24 at 7:37 PM
streetinsider.com logoForm 4 OvaScience, Inc. For: Jun 21 Filed by: CAPELLO JEFFREY D - StreetInsider.com
www.streetinsider.com - June 24 at 12:48 AM
News IconBRIEF-OvaScience appoints Christopher Kroeger as CEO
www.businessinsider.com - June 23 at 8:51 AM
businesswire.com logoOvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - June 22 at 7:14 AM
streetinsider.com logoOvaScience (OVAS) Completes Enrollment in OvaPrime Clinical Study in Women with POI or POR
www.streetinsider.com - June 13 at 7:12 PM
seekingalpha.com logoOvaScience completes enrollment in OvaPrime study - Seeking Alpha
seekingalpha.com - June 13 at 10:34 AM
seekingalpha.com logoOvaScience beats by $0.01, misses on revenue
seekingalpha.com - May 12 at 12:34 AM
businesswire.com logoOvaScience to Host First Quarter 2017 Financial Results Conference Call
www.businesswire.com - May 3 at 7:57 PM
prnewswire.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In OvaScience, Inc. To ... - PR Newswire (press release)
www.prnewswire.com - April 21 at 9:05 AM
reuters.com logoBRIEF-Ecor1 Capital Llc reports a 9.9 pct passive stake in Ovascience as of march 23 - SEC Filing
www.reuters.com - March 31 at 7:12 PM
prnewswire.com logoLifshitz & Miller LLP Files Class Action Lawsuit against OvaScience, Inc. - PR Newswire (press release)
www.prnewswire.com - March 30 at 12:53 AM
nasdaq.com logoOvaScience (OVAS) Shares March Higher, Can It Continue? - Nasdaq
www.nasdaq.com - March 26 at 8:14 AM
us.rd.yahoo.com logoOvaScience, Inc. (OVAS) Looks Good: Stock Up 9.6% Higher
us.rd.yahoo.com - March 23 at 7:35 PM
streetinsider.com logoForm 4 OvaScience, Inc. For: Mar 02 Filed by: Dipp Michelle - StreetInsider.com
www.streetinsider.com - March 8 at 3:45 PM
streetinsider.com logoForm 4 OvaScience, Inc. For: Mar 02 Filed by: Couturier Christophe - StreetInsider.com
www.streetinsider.com - March 8 at 9:17 AM
reuters.com logoBRIEF-Ovascience reports Q4 loss per share $0.64
www.reuters.com - March 2 at 7:17 PM
us.rd.yahoo.com logoOvaScience Reports Fourth Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - March 2 at 7:17 PM
sg.finance.yahoo.com logoOvaScience reports 4Q loss
us.rd.yahoo.com - March 2 at 7:17 PM
biz.yahoo.com logoOVASCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 2 at 7:17 PM
biz.yahoo.com logoQ4 2016 OvaScience Inc Earnings Release - After Market Close
biz.yahoo.com - March 2 at 8:45 AM
biz.yahoo.com logoOvaScience Inc Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - March 2 at 8:45 AM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of OvaScience, Inc. - Business Wire (press release)
www.businesswire.com - February 16 at 6:42 PM
prnewswire.com logoBiotech Stocks Under Scanner -- Kite Pharma, BioPharmX ... - PR Newswire (press release)
www.prnewswire.com - January 23 at 9:36 AM

Social

Chart

OvaScience (OVAS) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.